Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

Status Withdrawn

Clinical Trial Summary

This study evaluates the non-inferiority of Cefaliv® compared to Neosaldina® in the treatment of migraine attack in two hundred and sixteen adults of both sexes with age between eighteen and sixty five years old. The first Half of participants will receive Cefaliv®, the other half will receive Neosaldina®.

Clinical Trial Description

Cefaliv® is a combination of 3 drugs: dihydroergotamine mesylate, dipyrone sodium, and caffeine. The dihydroergotamine mesylate interacts with the serotonergic, dopaminergic and noradrenergic receptors, but it's mechanism is not totally known. The dipyrone is a non-steroidal antiinflammatory which has an analgesic, antiinflammatory and antipyretic effect. And the caffeine presents mechanisms that are not totally clear, but it may relieves the pain by activating of the central noradenosine pathway (pain suppressing system). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02706015
Study type	Interventional
Source	Ache Laboratorios Farmaceuticos S.A.
Contact
Status	Withdrawn
Phase	Phase 3
Start date	October 2020
Completion date	July 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Not yet recruiting	`NCT05943457` - Vitamin K2 Supplementation in Adult Episodic Migraine	N/A
Completed	`NCT01211145` - Zomig - Treatment of Acute Migraine Headache in Adolescents	Phase 4
Completed	`NCT00530517` - A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack	Phase 2
Completed	`NCT00898677` - Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)	Phase 3
Completed	`NCT03971071` - A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache	Phase 4
Terminated	`NCT02375789` - Intranasal Cooling for Symptomatic Relief of Migraine	N/A
Completed	`NCT02518464` - Ticagrelor Therapy for RefrACTORy Migraine Study	Phase 4
Terminated	`NCT00391755` - A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches	Phase 4
Completed	`NCT03401346` - Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults	Phase 1
Completed	`NCT05085483` - Ketone for Migraine Prevention	N/A
Completed	`NCT01604785` - Low-dose Propofol for Pediatric Migraine	Phase 2/Phase 3
Terminated	`NCT00804973` - Study in Participants With Acute Migraines Headaches	Phase 2
Completed	`NCT03341689` - Psilocybin for the Treatment of Migraine Headache	Phase 1
Completed	`NCT01630044` - Neurostimulation Device for Treatment of Migraine Headache	N/A
Active, not recruiting	`NCT00285402` - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine	Phase 2
Completed	`NCT00203255` - Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache	N/A
Recruiting	`NCT06046508` - Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
Active, not recruiting	`NCT04584762` - Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine	N/A
Terminated	`NCT03099070` - Acute Stress Response in Migraine Sufferers	N/A